Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic
Open Access
- 10 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in American Journal of Clinical Dermatology
- Vol. 21 (3), 307-311
- https://doi.org/10.1007/s40257-020-00514-2
Abstract
Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has spread rapidly worldwide and has been shown to have a wide spectrum of severity. COVID-19 has become a public health emergency of relevant international concern, and it was declared a pandemic by the World Health Organization on 11 March, 2020. SARS-CoV-2 infection in severe cases involves the host response as an important contributor to the disease process and tissue damage, mainly due to dysregulated and excessive innate immune responses. The primary immune response leads to viral clearance in the majority of cases. However, in a subgroup of patients, the secondary immune response may be exaggerated, leading to inflammatory-induced lung injury and other complications including pneumonitis, acute respiratory distress syndrome, respiratory failure, shock, organ failure, and potentially death. Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, are therapeutically managed with biologic and non-biologic immunosuppressive and immunomodulatory drugs. The outbreak of COVID-19 affects the management of these chronic conditions, not only for those who are already receiving treatment but also for those who are about to start a new treatment to control their disease. In this article, the management of cutaneous immune-mediated diseases during the COVID-19 pandemic is discussed.Keywords
This publication has 43 references indexed in Scilit:
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritisAutoimmunity Reviews, 2020
- The protective and pathogenic roles of IL-17 in viral infections: friend or foe?Open Biology, 2019
- Systemic rheumatic diseases: From biological agents to small moleculesAutoimmunity Reviews, 2019
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathiesJCI Insight, 2018
- Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmissionThe Lancet Infectious Diseases, 2018
- Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2018
- Distinct Immune Response in Two MERS-CoV-Infected Patients: Can We Go from Bench to Bedside?PLOS ONE, 2014
- Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS CoronavirusmBio, 2013
- Community acquired respiratory and gastrointestinal viral infectionsCurrent Opinion in Infectious Diseases, 2012